A combined index of cardiac biomarkers as a risk factor for early cardiovascular mortality in hemodialysis patients

Bargnoux, Anne-Sophie; Moréna, Marion; Jaussent, Isabelle; Maurice, François; Chalabi, Lotfi; Leray‐Moragues, Hélène; Terrier, Nathalie; Dupuy, Anne‐Marie; Badiou, Stéphanie; Canaud, Bernard; Cristol, Jean‐Paul

doi:10.1515/cclm-2012-0664

Cited by 13 publications

(8 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, an update of ACC/AHA guidelines stated that the use of myocardial fibrosis biomarkers such as sST2 might be considered for predicting risk of hospitalization and death in patients with chronic HF and potentially added to natriuretic peptide biomarker levels in their prognostic value [ 34 ]. Our study confirms that hs-cTnT, CRP, and to a lesser extent NT-proBNP alone are predictive of poor outcome, as described in a hemodialysis population [ 38 ]. Yet, sST2 alone does not allow CV events or death composite outcome prognosis in nondialyzed CKD patients.…”

Section: Discussionsupporting

confidence: 90%

sST2 as a New Biomarker of Chronic Kidney Disease-Induced Cardiac Remodeling: Impact on Risk Prediction

Plawecki

Moréna

Kuster

et al. 2018

Mediators of Inflammation

Self Cite

View full text Add to dashboard Cite

Heart failure is the most frequent cardiac complication of chronic kidney disease (CKD). Biomarkers help identify high-risk patients. Natriuretic peptides (BNP and NT-proBNP) are largely used for monitoring patients with cardiac failure but are highly dependent on glomerular filtration rate (GFR). Soluble suppression of tumorigenicity 2 (sST2) biomarker is well identified in risk stratification of cardiovascular (CV) events in heart failure. Furthermore, sST2 is included in a bioclinical score to stratify mortality risk. The aims of this study were to evaluate (i) the interest of circulating sST2 level in heart dysfunction and (ii) the bioclinical score (Barcelona Bio-Heart Failure risk calculator) to predict the risk of composite outcome (major adverse coronary events) and mortality in the CKD population. A retrospective study was carried out on 218 CKD patients enrolled from 2004 to 2015 at Montpellier University Hospital. sST2 was measured by ELISA (Presage ST2® kit). GFR was estimated by the CKD-EPI equation (eGFR). Indices of cardiac parameters were performed by cardiac echography. No patient had reduced ejection fraction. 112 patients had left ventricular hypertrophy, and 184 presented cardiac dysfunction, with structural, functional abnormalities or both. sST2 was independent of age and eGFR (ρ = 0.05, p = 0.44, and ρ = −0.07, p = 0.3, respectively). Regarding echocardiogram data, sST2 was correlated with left ventricular mass index (ρ = 0.16, p = 0.02), left atrial diameter (ρ = 0.14, p = 0.04), and volume index (ρ = 0.13, p = 0.05). sST2 alone did not change risk prediction of death and/or CV events compared to natriuretic peptides. Included in the Barcelona Bio-Heart Failure (BCN Bio-HF) score, sST2 added value and better stratified the risk of CV events and/or death in CKD patients (p < 0.0001). To conclude, sST2 was associated with cardiac remodeling independently of eGFR, unlike other cardiac biomarkers. Added to the BCN Bio-HF score, the risk stratification of death and/or CV events in nondialyzed CKD patients was highly improved.

show abstract

Section: Discussionsupporting

confidence: 90%

sST2 as a New Biomarker of Chronic Kidney Disease-Induced Cardiac Remodeling: Impact on Risk Prediction

Plawecki

Moréna

Kuster

et al. 2018

Mediators of Inflammation

Self Cite

View full text Add to dashboard Cite

show abstract

“…The combined index of cardiovascular risk factors could supply additional information about cardiovascular mortality in HD patients (32). However, in our study there was no correlation between the cardiac biomarkers.…”

Section: Türk Nefroloji Diyaliz Ve Transplantasyon Dergisi Turkish Necontrasting

confidence: 63%

Association Between New Cardiac Biomarkers and Cardiovascular Abnormalities in Asymptomatic Hemodialysis Patients

Bardak¹,

Sari²,

Horoz³

et al. 2017

Turk Neph Dial Transpl

View full text Add to dashboard Cite

“…25-29 Furthermore, research thus far has generated conflicting results. Recently, Bargnoux et al 25 suggested that a combination of TnI, NT-proBNP, and CRP levels possibly improved risk assessment for short-term (<2 years) mortality in 140 HD patients. In their study, BNP and CRP were independent predictors of mortality but not TnI, probably because of the small study population.…”

Section: Previous Multimarker Studiesmentioning

confidence: 99%

Multimarker Approach to Risk Stratification for Long-Term Mortality in Patients on Chronic Hemodialysis

Ishii

Kitagawa

Kuno

et al. 2015

Circ J

View full text Add to dashboard Cite

A combined index of cardiac biomarkers as a risk factor for early cardiovascular mortality in hemodialysis patients

Abstract: A combined index of cardiovascular risk factors could provide supplementary risk stratification in HD patients for early cardiovascular mortality, strongly supporting the annual routine determination of these biomarkers.

Cited by 13 publications

References 42 publications

sST2 as a New Biomarker of Chronic Kidney Disease-Induced Cardiac Remodeling: Impact on Risk Prediction

sST2 as a New Biomarker of Chronic Kidney Disease-Induced Cardiac Remodeling: Impact on Risk Prediction

Association Between New Cardiac Biomarkers and Cardiovascular Abnormalities in Asymptomatic Hemodialysis Patients

Multimarker Approach to Risk Stratification for Long-Term Mortality in Patients on Chronic Hemodialysis

Contact Info

Product

Resources

About